Skip to content Provide accessibility feedback
For Providers
For Patients
Customer Stories
About Us
Contact Us
Magnifying glass Search

Volpara has entered into a Scheme Implementation Agreement with Lunit, Inc.

Clinically validated, AI-powered software for personalized screening and early detection of breast cancer.

Map of clinics using Volpara in the US

2,000+

Facilities use Volpara Health software for early detection of breast cancer, including top US cancer screening centers.

Mammogram-Technologist-with-patient2-optimise

5,600+

Mammography technologists rely on Volpara Health to improve mammogram quality.

Volpara gives us confidence that we did the best possible job for our patients.

– Deborah Hamel, Quality Assurance Manager, Derry Imaging

women-group-breast-density-optimise

16.5 m+

Women across 40 countries have had their breast density assessed by Volpara Health.

Knowing precisely how dense my breasts are gave me a clear path for screening.

– Patient, Reno Diagnostic Centers

100 m+

Mammography and tomosynthesis images have been deidentified and analyzed by Volpara Health.

Every image we evaluate helps us evolve and improve our software, creating a path toward a healthier future.

– Lester Litchfield, Head of Data Science, Volpara Health

Trusted by Healthcare Leaders

Get ready for 2024

January 1, 2024

New NAPBC Standards

The new NAPBC Standards Manual (2024) is a shift to more personalized care delivery with greater use of risk assessment and preventative protocols.

September 10, 2024

New FDA Density Rule

The Food & Drug Administration has updated the Mammography Quality Standards Act (MQSA) to make patient breast density notification a federal requirement.

What's New

Explore events, resources and viewpoints.

Event

NCoBC 2024

Blog
24 Oct 2023

AI that Works in Breast Imaging: Volpara literally wrote the eBook!

Blog
27 Jun 2023

Volpara is Microsoft’s 2023 Healthcare & Life Sciences Partner of the Year

FDA national breast density notification requirement